featured
Discontinuation vs Continuation of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumours
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Lancet Oncol 2024 Aug 07;[EPub Ahead of Print], JY Blay, Q Devin, F Duffaud, M Toulmonde, N Firmin, O Collard, E Bompas, B Verret, I Ray-Coquard, S Salas, C Henon, C Honoré, M Brahmi, A Dufresne, M Pracht, A Hervieu, N Penel, F Bertucci, M Rios, E Saada-Bouzid, P Soibinet, D Perol, S Chabaud, A Italiano, AL CesneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.